Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Cannabinoid chemistry: an overview

  • Chapter
Cannabinoids as Therapeutics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Li HL (1974) An archeological and historical account of cannabis in China. Econ Bot 28: 437–448

    Google Scholar 

  2. Wood TB, Spivey WTN, Easterfield TH (1896) Charas, the resin of Indian hemp. J Chem Soc 69: 539–546

    Google Scholar 

  3. Wood TB, Spivey WTN, Easterfield TH (1899) Cannabinol. Part I. J Chem Soc 75: 20–36

    Google Scholar 

  4. Cahn RS (1932) Cannabis indica resin, Part III. The constitution of Cannabinol. J Chem Soc 1342–1353

    Google Scholar 

  5. Jacob A, Todd AR (1940) Cannabis indica. Part II. Isolation of cannabidiol from egyptian hashish. Observations on the structure of cannabinol. J Chem Soc 649–653

    Google Scholar 

  6. Ghosh R, Todd AR, Wilkinson S (1940) Cannabis indica, Part V. The synthesis of cannabinol. J Chem Soc 1393–1396

    Google Scholar 

  7. Adams R, Baker BR, Wearn RB (1940) Structure of cannabinol. III. Synthesis of cannabinol, l-Hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran. J Am Chem Soc 62: 2204–2207

    Article  Google Scholar 

  8. Adams R, Wolff H, Cain CK, Clark JH (1940) Structure of cannabidiol. V. Position of the alicyclic double bonds. JAm Chem Soc 62: 2215–2219

    Article  Google Scholar 

  9. Adams R, Loewe S, Pease DC, Cain CK, Wearn RB, Baker BR, Wolff H (1940) Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydrocannabinols. JAm Chem Soc 62: 2566–2567

    Article  Google Scholar 

  10. Adams R, Baker BR (1940) Structure of cannabidiol. VII. A method of synthesis of a tetrahydrocannabinol which possesses marihuana activity. JAm Chem Soc 62: 2405–2408

    Article  Google Scholar 

  11. Adams R, Pease DC, Cain CK, Baker BR, Clark JH, Wolff H, Wearn RB (1940) Conversion of cannabidiol to a product with marihuana activity. A type reaction fo synthesis of analogous substances. Conversion of cannabidiol to cannabinol. JAm Chem Soc 62: 2245–2246

    Article  Google Scholar 

  12. Ghosh R, Todd AR, Wilkinson S (1940) Cannabis indica, Part IV. The synthesis of some tetrahydrodibenzopyran derivatives. J Chem Soc 1121–1125

    Google Scholar 

  13. Krejčí Z, Šantavý F (1955) Isolace dalsˇích látek z listí indickeho konopí Cannabis sativa L. Acta Univ Palacki Olomuc 6: 59–66

    Google Scholar 

  14. Kabelík J, Krečí Z, Šantavý F (1960) Cannabis as a medicament. Bull Narc 12: 5–23

    Google Scholar 

  15. Mechoulam R, Shvo Y (1963) The structure of cannabidiol. Tetrahedron 19: 2073–2078

    Article  PubMed  Google Scholar 

  16. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. JAm Chem Soc 86: 1646–1647

    Article  Google Scholar 

  17. Mechoulam R, Gaoni Y (1967) The absolute configuration of Δ1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 8: 1109–1111

    Article  Google Scholar 

  18. Hively RL, Mosher WA, Hoffmann FW (1966) Isolation of trans-Δ6-tetrahydrocannabinol from marijuana. JAm Chem Soc 88: 1832–1833

    Article  Google Scholar 

  19. Gaoni Y, Mechoulam R (1964) The structure and synthesis of cannabigerol, a new hashish constituent. Proc Chem Soc 82

    Google Scholar 

  20. Gaoni Y, Mechoulam R (1966) Cannabichromene, a new active principle in hashish. Chem Commun 20–21

    Google Scholar 

  21. Claussen U, v Spulak F, Korte F (1966) Zur chemischen Klassifizierung von Pflanzen XXXI. Haschisch X. Cannabichromen, ein neuer Haschisch-Inhaltsstoff. Tetrahedron 22: 1477–1479

    Article  Google Scholar 

  22. Crombie L, Ponsford R (1968) Hashish components. Photochemical production of cannabicyclol from cannabichromene. Tetrahedron Lett 9: 5771–5772

    Article  Google Scholar 

  23. Mechoulam R, Gaoni Y (1965) The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron 21: 1223–1229

    Article  PubMed  Google Scholar 

  24. Korte F, Haag M, Claussen U (1966) Tetrahydrocannabinol-carbonsdiure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77, 862

    Google Scholar 

  25. Yamauchi T, Shoyama Y, Aramaki H, Azuma T, Nishioka I (1967) Tetrahydrocannabinolic acid a genuine substance of tetrahydrocannabinol. Chem Pharm Bull 15, 1075

    PubMed  Google Scholar 

  26. Mechoulam R, Ben-Zvi Z, Yagnitinsky B, Shani A (1969) A new tetrahydrocannabinolic acid. Tetrahedron Lett 10: 2339–2341

    Article  Google Scholar 

  27. Krejčí Z, Šantavý F (1975) Isolation of two new cannabinoid acids from Cannabis sativa L. of Czechoslovak origin. Acta Univ Olomuc, Fac Med 74: 161–166

    Google Scholar 

  28. Shani A, Mechoulam R (1974) Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron 30: 2437–2446

    Article  Google Scholar 

  29. Gohda H, Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H (1987) The formation mechanism of cannabielsoin from cannabidiol with guinea-pig hepatic-microsomal enzymes. J Pharm Sci 76: S32

    Google Scholar 

  30. Mechoulam R, Ben-Zvi Z (1969) Carboxylation of resorcinols with methyl magnesium carbonate. Synthesis of cannabinoid acids. Chem Commun 343–344

    Google Scholar 

  31. Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. In: L Zechmeister (ed.): Progress in the chemistry of organic natural products (Fortschritte der Chemie Organischer Naturstoffe), vol. XXV, Springer Verlag, Wien, 175–213

    Google Scholar 

  32. Mechoulam R, ed (1973) Marijuana. Chemistry, Metabolism, Pharmacology and Clinical Effects. Academic Press, New York

    Google Scholar 

  33. Turner CE, Elsohly MA, Boeren EG (1980) Constituents of Cannabis sativa L. 17. A review of the natural constituents. JNat Prod 43: 169–234

    Article  Google Scholar 

  34. Hanuš L (1987) Biogenesis of cannabinoid substances in the plant. Acta Univ Palacki Olomuc, Fac Med 116: 47–53

    Google Scholar 

  35. Taura F, Morimoto S, Shoyama Y, Mechoulam R (1995) First direct evidence for the mechanism of delta(1)-tetrahydrocannabinolic acid biosynthesis. J Am Chem Soc 117: 9766–9767

    Article  Google Scholar 

  36. Turner CE, Hadley K (1973) Constituents of Cannabis sativa L. II. Absence of cannabidiol in an African variant. J Pharm Sci 62: 251–255

    PubMed  Google Scholar 

  37. KrejčÍ Z, Hanug L, Yoshida T, Braenden OJ (1975) The effect of climatic and ecologic conditions upon the formation and the amount of cannabinoid substances in the cannabis of various provenance. Acta Univ Olomuc, Fac Med 74: 147–160

    Google Scholar 

  38. Holley JH, Hadley KW, Turner CE (1975) Constituents of Cannabis sativa L. XI: Cannabidiol and cannabichromene in samples of known geographical origin. J Pharm Sci 64: 892–895

    PubMed  Google Scholar 

  39. Morimoto S, Komatsu K, Taura F, Shoyama Y (1997) Enzymological evidence for cannabichromenic acid biosynthesis. J Nat Prod 60: 854–857

    Article  Google Scholar 

  40. Kushima H, Shoyama Y, Nishioka I (1980) Cannabis. XII. Variations of cannabinoid contents in several strains of Cannabis sativa L. with leaf-age, season and sex. Chem Pharm Bull 28: 594–598

    Google Scholar 

  41. Devane WA, Dysarz FA 3rd Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605–613

    PubMed  Google Scholar 

  42. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949

    PubMed  Google Scholar 

  43. Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231: 313–314

    Article  PubMed  Google Scholar 

  44. Hanuš L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36: 3032–3034

    Article  PubMed  Google Scholar 

  45. Mechoulam R, Ben-Shabat S, Hanug L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to the peripheral cannabinoid receptors. Biochem Pharmacol 50: 83–90

    Article  PubMed  Google Scholar 

  46. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97

    Article  PubMed  Google Scholar 

  47. Hanug L, Abu-Lafi S, Fride E, Breuer A, Shalev DE, Kustanovich I, Vogel Z, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, a novel endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98: 3662–3665

    Article  PubMed  Google Scholar 

  48. Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T (2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 85: 1374–1381

    Article  PubMed  Google Scholar 

  49. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao JQ, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020–1024

    Article  PubMed  Google Scholar 

  50. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Proc Natl Acad Sci USA 99: 8400–8405

    Article  PubMed  Google Scholar 

  51. Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D, Bisogno T, Di Marzo V, Kuklev D, Rossi JC et al. (2001) Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 11: 447–449

    Article  PubMed  Google Scholar 

  52. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. J Biochem 351: 817–824

    Article  Google Scholar 

  53. Walker JM, Krey JF, Chu CJ, Huang SM (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121: 159–172

    Article  PubMed  Google Scholar 

  54. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686–91

    Article  PubMed  Google Scholar 

  55. Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000) Oxidative metabolism of anandamide. Prostag Oth Lipid M 61: 29–41

    Article  Google Scholar 

  56. Johnson MR, Melvin LS (1983) 2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives. US Patent 4,371,720, Pfizer Inc

    Google Scholar 

  57. Melvin LS, Johnson MR, Milne GM (1983) A cannabinoid derived analgesic (CP-55,940). In: Abstracts of Papers, 186th Natl. Meet. American Chemical. Soc., Washington, D.C., August 1983. American Chemical Society, Washington, D.C., Abstr. MEDI, 2

    Google Scholar 

  58. Johnson MR, Melvin LS (1986) The discovery of nonclassical cannabinoid analgetics. In: R Mechoulam (ed.): Cannabinoids as therapeutic agents. CRC Press, Boca Raton, FL, pp 121–145

    Google Scholar 

  59. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol 34: 605–613

    PubMed  Google Scholar 

  60. Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular-cloning of a human cannabinoid receptor which is also expressed in testis. J Biochem 279: 129–134

    Google Scholar 

  61. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TUC, Hiltunen AJ, Consroe P (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44: 762–764

    PubMed  Google Scholar 

  62. Mechoulam R, Lander N, Breuer A, Zahalka J (1990) Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1: 315–319

    Article  Google Scholar 

  63. Little PJ, Compton DR, Mechoulam R, Martin B (1989) Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behavior 32: 661–666

    Article  Google Scholar 

  64. Järbe TUC, Hiltunen AJ, Mechoulam R (1989) Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exper Ther 250: 1000–1005

    Google Scholar 

  65. Devane WA, Breuer A, Sheskin T, Jarbe TUC, Eisen M, Mechoulam R (1992) A novel probe for the cannabinoid receptor. J Med Chem 35: 2065–2069

    Article  PubMed  Google Scholar 

  66. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle A, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35: 3135–3141

    Article  PubMed  Google Scholar 

  67. Burstein SH (2000) Ajulemic Acid (CT3): A potent analog of the acid metabolites of THC. Curr Pharmaceut Design 6: 1339–1345

    Article  Google Scholar 

  68. Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S (2001) Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 62: 755–763

    Article  PubMed  Google Scholar 

  69. Liu JL, Li H, Burstein SH, Zurier RB, Chen JD (2003) Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63: 983–992

    Article  PubMed  Google Scholar 

  70. Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zuriera RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108: 95–102

    Article  PubMed  Google Scholar 

  71. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in marine collagen-induced arthritis. Arthritis Rheum 50: 985–998

    Article  PubMed  Google Scholar 

  72. Bell MR, D’Ambra TE, Kumar V, Eissenstat MA, Herrmann JL Jr, Wetzel JR, Rosi D, Philion RE, Daum SJ, Hlasta DJ et al. (1991) Antinociceptive (aminoalkyl)indoles. J Med Chem 34: 1099–1110

    Article  PubMed  Google Scholar 

  73. D’Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC et al. (1992) Conformationally restrained analogs of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35: 124–135

    Article  PubMed  Google Scholar 

  74. Eissenstat MA, Bell MR, D’Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. JMed Chem 38: 3094–3105

    Article  Google Scholar 

  75. Haycock DA, Kuster JE, Stevenson JI, Ward SJ, D’Ambra T (1990) Characterization of aminoalkylindole binding: selective displacement by cannabinoids. Probl Drug Depend NIDA Res Monogr 105: 304–305

    Google Scholar 

  76. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Nl1iat G, Caput D et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244

    Article  PubMed  Google Scholar 

  77. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284: 291–297

    PubMed  Google Scholar 

  78. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644–650

    PubMed  Google Scholar 

  79. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung M, Martin BR, Abood ME (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, 2 SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377: 117–125

    Article  PubMed  Google Scholar 

  80. HanuĆ L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Fride E, Mechoulam R (1999) HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228–14233

    Article  PubMed  Google Scholar 

  81. Panikashvili D, Simeonidou C, Ben-Shabat S, HanuĆ L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527–531

    Article  PubMed  Google Scholar 

  82. Mauler F, Mittendorf J, Horváth E, De Vry J (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-l-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302: 359–368

    Article  PubMed  Google Scholar 

  83. De Vry J, Jentzsch KR (2002) Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. J Pharmacol Exp Ther 457: 147–152

    Google Scholar 

  84. Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E (2003) Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 989: 99–111

    Article  PubMed  Google Scholar 

  85. Mauler F Horváth E, De Vry J, Jäger R, Schwarz T Sandmann S, Weinz C, Heinig R, Böttcher M (2003) BAY 38-7271: A Novel Highly Selective and Highly Potent Cannabinoid Receptor Agonist for the Treatment of Traumatic Brain Injury. CNS Drug Reviews 9: 343–358

    PubMed  Google Scholar 

  86. Pharmos Corp. (2002) Bicyclic cannabinoid. Poster, Society for Neuroscience 32nd Annual Meeting, 3–7 November 2002, Orlando, FL

    Google Scholar 

  87. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37: 1889–1893

    Article  PubMed  Google Scholar 

  88. Khanolkar AD, Abadji V, Lin S, Hill WAG, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39: 4515–4519

    Article  PubMed  Google Scholar 

  89. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949–1955

    Article  PubMed  Google Scholar 

  90. Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makliyannis A, Consroe P, Roeske WR, Yamamura HI (1997) AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci 61, PL115–PL118

    Article  PubMed  Google Scholar 

  91. Hosohata Y, Quock RM, Hosohata K, Malaiyannis A, Consroe P, Roeske WR, Yamamura HI (1997) AM630 antagonism of cannabinoid-stimulated [S-35]GTP gamma S binding in the mouse brain. Eur J Pharmacol 321, R1–R3

    Article  PubMed  Google Scholar 

  92. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A (1998) Imaging the Brain Marijuana Receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70: 417–423

    PubMed  Google Scholar 

  93. Ibrahim MM, Deng H, Zvonok A (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529–10533

    Article  PubMed  Google Scholar 

  94. Luk T, Jin WZ, Zvonok A, Lu D, Lin XZ, Chavkin C, Makriyannis A, Mackie K (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB 1 cannabinoid receptor agonist. Br J Pharm 142: 495–500

    Article  Google Scholar 

  95. Gifford AN, Makriyannis A, Volkow ND, Gatley SJ (2002) In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121: 65–72

    Article  PubMed  Google Scholar 

  96. Stoit AR, Lange JH, Hartog AP, Ronken E, Tipker K, Stuivenberg HH, Dijksman JA, Wals HC, Kruse CG (2002) Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull 50: 1109–1113

    Article  PubMed  Google Scholar 

  97. Barth F (1998) Cannabinoid receptor agonists and antagonists. Expert Opin Ther Patents 8: 301–313

    Article  Google Scholar 

  98. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, Rochette C, Sawyer N, Slipetz DM, Tremblay N et al. (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6: 2263–2268

    Article  Google Scholar 

  99. Mussinu JM, Ruiu S, Mule AC, Pau A, Carai MAM, Loriga G, Murineddu G, Pinna GA (2003) Tricyclic pyrazoles. part 1: Synthesis and biological evaluation of novel 1,4-dihydroinde-no[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem 11: 251–263

    Article  PubMed  Google Scholar 

  100. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39: 3875–3877

    Article  PubMed  Google Scholar 

  101. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905–2914

    Article  PubMed  Google Scholar 

  102. Huffman JW, Bushell SM, Miller JRA, Wiley JL, Martin BR (2002) 1-methoxy-,1-deoxy-11-hydroxy-and 11-Hydroxy-l-methoxy-Δ8-tetrahydrocannabinols: New selective ligands for the CB2 receptor. Bioorg Med Chem 10: 4119–4129

    Article  PubMed  Google Scholar 

  103. Lange JHM, Coolen HKAC, van Stuivenberg HH, Dijksman JAR, Herremans AHJ, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W et al. (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47: 627–643

    Article  PubMed  Google Scholar 

  104. Hertzog DL (2004) Recent advances in the cannabinoids. Expert Opin Ther Patents 14: 1435–1452

    Article  Google Scholar 

  105. Brain C T, Dziadulewicz E K, Hart T W (2003) Chinazolinonderivate und deren verwendung als CB-agonisten. Novartis AG (CH); Novartis Pharma GMBH (AT): W003066603.

    Google Scholar 

  106. Makriyannis A, Liu Q (2003) Heteroindane: Eine neue klasse hochwirksamer cannabimimetischer liganden. Univ. Connecticut (US): W003035005.

    Google Scholar 

  107. Kozlowski J A, Shankar B B, Shih N Y, Tong L (2004) Cannabinoid receptor agonists. Schering Corp. (US): W02004000807.

    Google Scholar 

  108. Kozlowski J A, Shih N Y, Lavey B J, Rizvi R K, Shankar B B, Spitler J M, Tong L, Wolin R, Wong M K (2004) Cannabinoid receptor ligands. Schering Corp. (US): W02004014825.

    Google Scholar 

  109. Page D, Walpole Ch, Yang H (2004) Preparation of benzimidazolecarboxamides as CB2 receptor agonists for treating pain and other disorders. AstraZeneca AB (Swed.): W004035548

    Google Scholar 

  110. Makriyannis, A., Lai, X Z, Lu D (2004) Preparation of novel biphenyl and biphenyl-like cannabinoids with binding affinities for the CB1 and CB2 cannabinoid receptor. Univ. Connecticut (US): W004017920.

    Google Scholar 

  111. Martin B R, Razdan R K (2003) Cannabinoids. Virginia Commonwealth Univ. (US): W003091189.

    Google Scholar 

  112. Makriyannis A, Deng H (2002) Novel cannabimimetic ligands. Univ. Connecticut (US): W002058636.

    Google Scholar 

  113. Kai H, Murashi T, Tomida M (2002) Medicinal composition containing 1,3-thiazine derivative. Shionogi ⇐p; Co. Ltd (JP): W002072562.

    Google Scholar 

  114. Yasui K, Morioka Y, Hanasaki K (2002) Antipruritics. Shionogi ⇐p; Co. Ltd (JP): W003070277.

    Google Scholar 

  115. Tada Y, Iso Y, Hanasaki K (2002) Pyridone derivative having affinity for cannabinoid 2-type receptor. Shionogi & Co. Ltd (JP): W002053543.

    Google Scholar 

  116. Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, Ruiu S, Gessa GL (2004) Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptor. Bioorg Med Chem 12: 1921–1933

    Article  PubMed  Google Scholar 

  117. Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson ALS, Bushell S, Tartal C, Hurst DP et al. (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg Med Chem 13: 89–112

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicinal Chemistry and Natural Products, Medical Faculty, The Hebrew University of Jerusalem, Ein Kerem Campus, 91120, Jerusalem, Israel

    Lumír O. Hanuš & Raphael Mechoulam

Authors
  1. Lumír O. Hanuš
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raphael Mechoulam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Faculty, Hebrew University, Ein Kerem, Jerusalem, 91010, Israel

    Raphael Mechoulam

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Hanuš, L.O., Mechoulam, R. (2005). Cannabinoid chemistry: an overview. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_2

Download citation

Publish with us

Policies and ethics

Search

Navigation